搜索

quanfu quanfu

Product Center

Homepage
/
News
/
Company news
/
Recombinant herpes zoster vaccine (CHO cell) IND application accepted

Recombinant herpes zoster vaccine (CHO cell) IND application accepted

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2024-02-23
  • Views:

(Summary description)On February 23, 2024, Ab&B Bio Tech CO., LTD. JS independently developed a class I new drug recombinant herpes zoster vaccine (CHO cell) IND application, which was accepted by the Drug Evaluation Center (CDE) of the State Medical Products Administration of China.

Recombinant herpes zoster vaccine (CHO cell) IND application accepted

(Summary description)On February 23, 2024, Ab&B Bio Tech CO., LTD. JS independently developed a class I new drug recombinant herpes zoster vaccine (CHO cell) IND application, which was accepted by the Drug Evaluation Center (CDE) of the State Medical Products Administration of China.

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2024-02-23 16:13
  • Views:
Information
On February 23, 2024, Ab&B Bio Tech CO., LTD. JS independently developed a class I new drug recombinant herpes zoster vaccine (CHO cell) IND application, which was accepted by the Drug Evaluation Center (CDE) of the State Medical Products Administration of China.
IMG_256
Source: Government Service Website of the Drug Evaluation Center of the National Medical Products Administration
 
Herpes zoster (HZ) is a kind of infectious diseases that mainly affects nerves and skin caused by reactivation of Varicella zoster virus (VZV). The main characteristics are clustered blisters distributed in a strip shape, accompanied by obvious neuralgia. The older the age, the more severe the neuralgia. This disease is common in patients with advanced age, immunodeficiency, and the use of immunosuppressants, and there is a certain recurrence rate. At present, there is no effective treatment for herpes zoster, and vaccination is an effective means of preventing herpes zoster.
Ab&B Bio Tech CO., LTD. JS always adheres to the principle of not making simple replicates and carries out independent innovation and research and development. The recombinant herpes zoster vaccine (CHO cells) that has been accepted this time utilizes multiple independent intellectual property innovative technologies, adjuvant systems, and officially authorized high expression cell matrices from the company. Preclinical studies have shown that this product can simultaneously induce the production of high levels of specific antibodies and CD4+T cell responses, with high immunogenicity, efficacy, and safety.
Scan the QR code to read on your phone
Previous: Received national level praise!
Next: Ab&B Bio Tech CO., LTD. JS invited to attend the China Ukraine Trade Cooperation Seminar
Previous: Received national level praise!
Next: Ab&B Bio Tech CO., LTD. JS invited to attend the China Ukraine Trade Cooperation Seminar

Relevant information

Have a project？Get a touch!

Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio

Contact

E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City

Quick view

Follow us

Copyright © 2022 Ab&B Bio-Tech CO.,LTD.JS All Rights Reserved.   Powered by:www.300.cn
Verification 苏ICP备16005775号-1
Search